Beyond the GLP-1RA weight loss ceiling - Pharmaceutical Technology

Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here? Eli Lilly’s retatrutide has crossed the 30% weight loss benchmark in some patients. Where do GLP-1RAs go from here? Triple agonist retatrutide, targeting glucagon-like peptide (GLP-1), glucagon, and glucagon-like peptide-1 (GIP), offers up to 30% weight loss in some patients. Experts question where innovation should be directed beyond that weight loss benchmark. Credit: Anna Hoychuk/Shutterstock.com On 21 May 21, 2026, Eli Lilly’s retatrutide achieved a historic first; as of June 2026, it is the only drug to produce an average weight…

Source: Pharmaceutical Technology